Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
ENTR-601-45 in Muscular Dystrophy, Duchenne: NCT07038824 Clinical Landscape Report 2026
16 September 2026
NCT07038824 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ENTR-601-44 in Exon 44 Skipping Mutation Duchenne Muscular Dystrophy: NCT07037862 Clinical Landscape Report 2026
16 September 2026
NCT07037862 clinical landscape for Exon 44 Skipping Mutation Duchenne Muscular Dystrophy: endpoints, sponsor, phase, geography, readouts, asset context and d…
9 min read
Etavopivat in Thalassemia: NCT07023029 Clinical Landscape Report 2026
16 September 2026
NCT07023029 clinical landscape for Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BBM-D101 in Muscular Dystrophy, Duchenne: NCT07058662 Clinical Landscape Report 2026
16 September 2026
NCT07058662 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Efgartigimod Alfa in Myasthenia Gravis: NCT07072988 Clinical Landscape Report 2026
16 September 2026
NCT07072988 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etranacogene dezaparvovec in Hemophilia B: NCT07080905 Clinical Landscape Report 2026
16 September 2026
NCT07080905 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rituximab in Neurolytic Block: NCT07071246 Clinical Landscape Report 2026
16 September 2026
NCT07071246 clinical landscape for Neurolytic Block: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Revlucabtagene Autoleucel in Lambert-Eaton Myasthenic Syndrome: NCT07085676 Clinical Landscape Report 2026
16 September 2026
NCT07085676 clinical landscape for Lambert-Eaton Myasthenic Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Descartes-08 in Dermatomyositis: NCT07089121 Clinical Landscape Report 2026
16 September 2026
NCT07089121 clinical landscape for Dermatomyositis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SGT-003 in Muscular Dystrophy, Duchenne: NCT07160634 Clinical Landscape Report 2026
16 September 2026
NCT07160634 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lipoic acid in Beta-Thalassemia: NCT07157722 Clinical Landscape Report 2026
16 September 2026
NCT07157722 clinical landscape for Beta-Thalassemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RN-1201 in Neuromyelitis Optica: NCT07105735 Clinical Landscape Report 2026
16 September 2026
NCT07105735 clinical landscape for Neuromyelitis Optica: endpoints, sponsor, phase, geography, readouts, asset context and development white space.